摘要
多发性骨髓瘤(MM)是不可治愈的血浆细胞瘤,占所有血液恶性肿瘤的约10%。最近,新出现的证据表明MM细胞和浸润性免疫细胞之间的骨髓相互作用的复杂性已被报道可促进肿瘤细胞的增殖,存活和耐药性。微小RNA(miRNA)是在细胞中具有调节功能的小的非编码RNA分子,其表达在不同恶性肿瘤中具有预测和预后价值。由于它们通过不同机制使免疫反应极化的能力,包括免疫细胞的分子重编程,MiRNA正在越来越受到关注。这一特征与miRNA模拟物或抑制剂的抗肿瘤活性一起使得miRNA网络成为新型抗MM治疗方法的有吸引力的研究领域。在这篇综述中,我们将讨论MM细胞与骨髓宿主免疫细胞间相互作用的最新进展,特别关注miRNA网络调制引起的分子和功能变化。我们终将指出治疗干预的潜在目标。
关键词: MicroRNA,miRNA,多发性骨髓瘤,免疫治疗,肿瘤免疫学,免疫反应。
图形摘要
Current Cancer Drug Targets
Title:Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Volume: 17 Issue: 9
关键词: MicroRNA,miRNA,多发性骨髓瘤,免疫治疗,肿瘤免疫学,免疫反应。
摘要: Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cells. This characteristic, together with the antitumor activity of miRNA mimics or inhibitors, make the miRNA network an attractive area of investigation for novel anti-MM therapeutic approaches. In this review, we will discuss the recent advances in the understanding of the interplay between MM cells and bone marrow resident immune cells, with special focus on the molecular and functional changes induced by miRNA network modulation. We will finally indicate potential targets for therapeutic intervention.
Export Options
About this article
Cite this article as:
Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170330154756
DOI https://dx.doi.org/10.2174/1568009617666170330154756 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Implication of Possible Therapies Targeted for the Tachykinergic System with the Biology of Neurokinin Receptors and Emerging Related Proteins
Recent Patents on CNS Drug Discovery (Discontinued) Discovery of Small Molecules that Target Autophagy for Cancer Treatment
Current Medicinal Chemistry Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies
Current Radiopharmaceuticals Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry N-glycomic Analysis of Z(IgA1) Partitioned Serum and Salivary Immunoglobulin A by Capillary Electrophoresis
Current Molecular Medicine Daclizumab: A Potential Asthma Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas
Current Medicinal Chemistry